New hope for Tough-to-Treat breast cancer: testing a powerful drug duo
NCT ID NCT07198724
Summary
This study is testing whether combining two drugs, elacestrant and trastuzumab deruxtecan, can help control advanced breast cancer that has grown despite prior hormone-based therapies. It will involve about 65 people with specific types of breast cancer (HR+/HER2-low or ultralow) that has spread. The research aims to find the safest, most effective dose and see if the combination can shrink tumors and delay cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.